Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Expanded access Approved for marketing Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Summary

The purpose of this study is to collect additional safety information on abiraterone acetate administered with prednisone to patients with metastatic castration-resistant prostate cancer (CRPC).

Timeline

Start: —
Primary completion: —
Completion: —

Publications

Sternberg CN, Castellano D, Daugaard G, Geczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ; Abiraterone Global EAP Investigators. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abiraterone acetate	Small molecule	1000 mg	Oral
Background	Prednisolone	Other / unclassified	5 mg	Oral
Background	Prednisone	Other / unclassified	5 mg	Oral

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications